NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Q1 Loss Of US$632.8 Million Tests Bullish Growth Narratives
ImmunityBio (IBRX) opened Q1 2026 with revenue of US$44.2 million and a basic EPS loss of US$0.62, alongside a net income loss of US$632.8 million, putting a sharp spotlight on how much cash the business is burning to drive its pipeline. The company has seen quarterly revenue move from US$7.6 million in Q4 2024 to US$16.5 million in Q1 2025, US$38.3 million in Q4 2025 and now US$44.2 million in Q1 2026, while quarterly basic EPS has stayed in loss territory over the same stretch. The key...